Results 61 to 70 of about 16,303 (230)
Longer FVIII: the 4th generation [PDF]
Blood, 2012 In this issue of Blood, Powell and colleagues present the first human data after the infusion of a new recombinant factor VIII (FVIII) product that when fused with the Fc fragment of IgG1 results in significantly prolonged half-life in the circulation.
openaire +2 more sources
Italian Patients Journey for Gene Therapy in Haemophilia A
Haemophilia, EarlyView.ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno +19 more
wiley +1 more source
PLoS ONE, 2015 ABO blood groups are known to influence the plasma level of von Willebrand factor (VWF), but little is known about the relationship between ABO and coagulation factor VIII (FVIII). We analyzed the influence of ABO genotypes on VWF antigen, FVIII activity,
Jaewoo Song +10 more
doaj +1 more source
Effect Size (%) of Covariates for FVIII activity and FVIII/VWF ratio.
, 2015 * Semipartial ω2 is the proportion of variability explained by each factor.a Model was defined as log FVIII = log VWF + ABO + environmental covariates (age, BMI, hypertension, diabetes, ever smoking status, and combination of race and gender).b Model was
David Couper (215307) +10 more
core +1 more source
Synthesis of Gold Nanoparticles Coated with Aspartic Acid and Their Conjugation with FVIII Protein and FVIII Antibody [PDF]
Indian Journal of Clinical Biochemistry, 2013 Carboxylate-modified gold nanoparticles (GNPs) were synthesized in a simple one-step process based on the reduction of tetrachloroauric acid by aspartic acid in water. GNPs were identified by UV-Vis spectroscopy, dynamic light scattering (DLS) and transmission electron microscopy.
Maryam Farahnak, Zarabi +6 more
openaire +2 more sources
Haemophilia, EarlyView.ABSTRACT Objectives To examine the association between patient‐reported outcome measures (PROMs) and objective measures of clinical performance in children, adolescents, and adults with haemophilia, highlighting their implications for person‐centered care.
Tatyane Oliveira Rebouças Brito +6 more
wiley +1 more source
The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity [PDF]
Blood, 2014 Key PointsInfusion of platelets containing FVIII triggers neither a primary nor memory anti-FVIII immune response in hemophilia A mice. Total body irradiation plus platelet-FVIII infusion suppresses anti-FVIII immune response.
Yingyu, Chen +7 more
openaire +2 more sources
Current State of Moderate Congenital Haemophilia A and the Need for Preventive Treatment
Haemophilia, EarlyView.ABSTRACT Introduction The severity of haemophilia A is classified by the degree of factor VIII (FVIII) deficiency, rather than by clinical manifestations. However, FVIII activity alone does not necessarily accurately reflect clinical severity such as bleeding tendency, and patients with mild‐to‐moderate haemophilia A can experience significant disease ...
Masahiro Takeyama +6 more
wiley +1 more source
The XX Factor in Hemophilia: Diagnostic, Therapeutic, and Research Gaps for Women and Girls
Haemophilia, EarlyView.ABSTRACT Introduction Hemophilia has traditionally been viewed as an X‐linked disorder affecting men and boys, with women and girls labeled as “carriers”, presumed to be clinically unaffected. This paradigm has contributed to under‐recognition, delayed diagnosis, and undertreatment of females with hemophilia‐associated genotypes despite an increasingly
Kelsey Uminski, Ellen Cusano
wiley +1 more source